2016 Regenerative Medicine Seed Grant Announcement
Deadline: July 11, 2016
The REM Seed Grant submission process is now closed. UPDATE 03/2017, check back soon for more information on 2017 request
University of Georgia, Georgia Institute of Technology, and Emory University under the Regenerative Engineering and Medicine Center (REM) announce the 2016-17 “Georgia Partners in Regenerative Medicine” seed grant program.
This funding mechanism is intended to stimulate new, collaborative research in regenerative medicine among UGA, Emory University, and GT investigators. The seed grant team must have a minimum of two investigators and must have an equal partnership of faculty from two of the participating institutions with budgets split between the universities as equally as possible.
While all proposals are welcome, proposals responsive to the following themes will be given funding priority for 2016-2017:
1. Modulation of Immunity and Host Responses to improve Regenerative Therapies
Local and systemic means to modulate the host environment to create more effective regenerative therapies (e.g. material, drug- or cell-based therapies that modulate inflammation/immune response, alter catabolic vs anabolic environment, address effects of aging and senescence, etc. to promote tissue regeneration)
2. Optimizing Regenerative Biomanufacturing
Means to enable scale-up and/or predicting quality (potency) of regenerative therapies during processing (e.g. new assays for potency prediction, new bioreactor or material technologies to promote scale-up of regenerative therapies)
This funding mechanism may support collaborative projects at earlier stages of development in the “high risk, high yield” category or projects with a high potential for clinical or industry translation. Synergies with other seed grant applications are encouraged in order to make maximally competitive future external grant applications. Any linkage or synergy with another application should be noted on the cover page of the application. Budgets for these proposals may not exceed $70,000. A total of 8-10 seed grants are expected to be awarded.
Deadline: 2016 CLOSED UPDATE, 2016 winners LINK
* All faculty members with primary appointments at Emory University, Georgia Institute of Technology, and University of Georgia are eligible to apply.
* Proposals from those addressing new questions or taking new approaches are encouraged.
* Teams must consist of UGA and Emory, UGA and Georgia Tech, or Georgia Tech and Emory investigators.
* Investigators may receive regenerative medicine seed grant funding for more than 3 years out of any 5 year period.
* The funding timeline for each award will be dependent on the type of funds used and the institution they are coming from. Details will be outlined in official award letters.
* Funds may be used for Ph.D. student/postdoc support, animal studies, research materials and supplies, and limited travel as related to the conduct of the research. Faculty salary support is not appropriate.
* Applicants are reminded that these are seed grants that are intended to promote the acquisition of extramural funding.
* The Regenerative Engineering and Medicine Center should be recognized in any grant or publication acknowledgements.
* The application must include a description of the long term funding strategy.
* Failure to submit a timely progress by Monday, April 24, 2017 report will result in ineligibility for future award opportunities from this seed grant program.
**Emory Exception - IF TEAM INCLUDES P.I. FROM EMORY
* The success of the research grant program will be measured by the publications and follow-on extramural funding from the seed grant and generation of intellectual property, and/or the initiation of clinical studies. Publications arising from a Emory / UGA or Georgia Tech / Emory seed grant should include the following citation in any publication, press release, or other document resulting from direct or indirect ACTSI support, “Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR00454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”
* Recipient must comply with the NIH public access policy and should sign the NOA acknowledging so.
* Please note that no clinical trial activity beyond phase IIA may be supported by this grant. For more information on the definition of clinical trials and phases, please refer to the NIH Grants Policy Statement at http://grants.nih.gov/grants/policy/nihgps_2013/. For all allowable clinical trials the grantee must register the clinical trial on the ClinicalTrials.gov Protocol Registration System Information Website at https://register.clinicaltrials.gov.
**Georgia Tech and UGA Exception
* For Georgia Tech and UGA students supported on these funds, their tuition will be waived.
* Prior recipients of seed grant funding must fill out a progress report of work completed under the prior funding. This will be collected on an on-line system and should include a summary of the work, publications and presentations and funding applied for and/or received. If extramural grant applications were unsuccessful, reviews and scores from those applications should be included.
* The format for these grants is the same as used by the NIH for standard R01 applications with the exception that there is a 3 page limit to the application (excluding budget and abstract).
Applications should include the proposal, a detailed budget using NIH forms and NIH format biosketches for the investigators.
DETAILED FORMATTING INSTRUCTION
• Application should include:
1. Cover page with the following information:
i. Title of Project
ii. Applicant Name(s), Titles, Email Addresses
iii. Department, Institution
iv. Requested Award Amount (Direct Costs)
v. Financial Manager’s Name and email address
2. Application must include an Abstract.
3. Biosketches of all key personnel (must include eRA Commons Username)
4. All applications must include the NIH PHS 398 Budget Form with justification. For each institution, please submit a separate NIH PHS 398 Budget Form with justification. Budget should total to $35,000 or less per institution ($70,000 max in total).
5. All Federal and university rules and regulations regarding the administration of grants apply to these funds. Costs subject to CAS approval, such as computers, general purpose equipment, office supplies and the like, may not be charged to this award.
6. Application must provide a statement on Human Subjects Protection, as outlined in the PHS 398 instructions (if applicable).
7. Applicant must provide the following items before funding is released (if relevant):
a. IRB approval letter
b. Approved protocol
b. IACUC approval
c. Any additional relevant certifications (CITI, etc.)
8. If Human Embryonic Stem Cells are being used, the applicant must include the registration number of the cell lines.
* Scoring will be based on standard NIH criteria with an emphasis on translational potential for strategic priority grants and innovation for the innovative research grants.
SUBMISSION & QUESTIONS
Technical questions regarding the program can be addressed by Michelle Wong. The proposal should be submitted to the REM website as a PDF as one complete document.
The REM Seed Grant submission process is now closed.